Treatment of chronic Hepatitis C with daclatasvir, sofosbuvir and simeprevir in patients from the reference hospital of infectology in central Brazil/ Tratamento da Hepatite C crônica com daclatasvir, sofosbuvir e simeprevir em pacientes do hospital de referência de infectologia do centro do Brasil

Bruna Menêzes Gonçalves, Symone Coelho Galvão Sirqueira, Rodrigo Sebba Aires, Mara Cristina Nolasco Sampaio, Jakeline Ribeiro Barbosa, Angela Ferreira Lopes, Danillo Rodrigues de Sá Godoi

Abstract


The drug treatment of hepatitis C represents a great therapeutic advance in favor of the elimination of the virus. The present study assessed the efficacy of treatment regimens involving direct action antivirals (DAAs), given to patients with chronic hepatitis C, attended at a referral hospital of infectology, central Brazil. This is a descriptive and cross - sectional study, based on the electronic database of the outpatient pharmacy, that evaluated the characteristics of patients and drug regimens involving DAA, from November 2015 to June 2017. Among 717 patients enrolled in this study, most of them had advanced liver fibrosis, were treatment naïve and HCV genotype 1 infected almost 80% of participants. A high efficacy of HCV treatment was achieved with 97% (95% CI: 94.9-98.2%) of SVR among the 431 patients who presented the results of viral load tests (HCV-RNA) at 12 weeks post-treatment. Patients infected with genotype 3 and who were cirrhotic had a lower SVR rate (87%). Treatment efficacy was not associated with age or sex among participants. The results of this study corroborate the findings in literature that showed a high efficacy of DAAs in the treatment of chronic hepatitis C, implemented through the clinical protocol and therapeutic guidelines for hepatitis C of the Ministry of Health in 2015. Many challenges must be overcome in order to combating viral hepatitis. In this context, the efficacy of HCV treatment it is an important issue to achieve the HCV elimination as a public health threat

Keywords


Chronic Hepatitis C, Drug Therapy, Sustained Virologic Response.

Full Text:

PDF

References


Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016;22(34):7824-40.

World Health Organization - WHO. Hepatitis C. Updated July 2018. Available online: https://www.who.int/en/news-room/fact-sheets/detail/hepatitis-c. (accessed on 05 february 2019).

Chalupa P, Holub M, Davidová A, Arientová S, Beran O. Immune response in the pathogenesis of hepatitis C virus infection. Epidemiol Mikrobiol Imunol. 2015 Oct;64(4):198-203.

Brazil. Ministry of Health. Secretariat of Health Surveillance. General Coordination of Development of Epidemiology in Services. Health Surveillance Guide. Brasília, DF: volume 2 / Ministry of Health - 1. ed. Current, 2017.

Ministry of Health (BR). Ministry of Health Surveillance. Department of STD, AIDS and Viral Hepatitis. The technical manual for the diagnosis of viral hepatitis [Internet]. Brasília: Ministry of Health; 2015 [quoted 2017 Nov 25]. 68 p. Available in: http://www.aids.gov.br/pt-br/pub/2015/manual-tecnico-para-o-diagnostico-dashepatites-virais

Ministry of Health (BR). Ministry of Health Surveillance. Department of STD, AIDS and Viral Hepatitis. Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections. Brasília: Ministry of Health; 2015. 101 p.

Ministry of Health (BR). Ministry of Health Surveillance. Department of STD, AIDS and Viral Hepatitis. Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections. Brasília: Ministry of Health; 2011. 106 p.

Ministry of Health (BR). Ministry of Health Surveillance. Department of STD, AIDS and Viral Hepatitis. Clinical Protocol and Therapeutic Guidelines for Hepatitis C and Coinfections: management of patients chronically infected by HCV genotype 1 and advanced fibrosis. Brasília: Ministry of Health; 2013. 52 p.

American Association for the Study of Liver Diseases (US). Hepatitis C guidance: AASLD-IDSA recommendations of testing, managing, and treating adults with hepatitis C virus. Hepatol. 2015 ago; 62(3): 932-954.

Ministry of Health (BR). Department of Epidemiological Surveillance. Viral Hepatitis: Brazil is aware [Internet]. Brasília: Ministry of Health; 2008 [quoted 2017 Nov 25]. 60 p. Available in: http://bvsms.saude.gov.br/bvs/publicacoes/hepatites_virais_brasil_atento_3ed.pdf

World Health Organization. Guidelines for the screening and treatment of persons with chronic hepatitis C infection [Internet]. Geneva: World Health Organization; 2016 [quoted 2017 Nov 25]. 140 p. Available in: http://www.who.int/hepatitis/publications/hepatitis-c-guidelines-2016/en/

Sirqueira EN. Evaluation of the therapeutic response rates of patients with hepatitis C undergoing therapies with new generation direct acting antivirals: a systematic review. Savior. Monografia [Graduation in Medicine] - Federal University of Bahia; 2016. 48p.

Ferreira VL. Free therapies for chronic hepatitis C: systematic review and meta-analysis. Curitiba. Dissertation [Master's Degree in Pharmaceutical Sciences] - Federal University of Paraná; 2016. 121p.

Cheinquer HH, Coelho HSM, Aires RS, Quintela ED, Lobato CO, Medeiros Filho JM et al. New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society. J Hepatol. 2017 abr; 66(1): S508.

Teixeira MA. Analysis of the safety and effectiveness of the treatment of chronic hepatitis C with protease inhibitors boceprevir and telaprevir in a reference center. Florianópolis. Dissertation [Master's Degree in Pharmacy] - Federal University of Santa Catarina; 2017. 112 p.

Rosa JA. Treatment of patients with chronic viral hepatitis C: experience of the application and monitoring of injectable drugs at Nereu Ramos Hospital, from 2005 to 2008. Florianópolis. Dissertation [Master's Degree in Pharmacy] - Federal University of Santa Catarina; 2009. 136 p.

Ministry of Health (BR). Ministry of Health Surveillance. Department of STD, AIDS and Viral Hepatitis. Epidemiological Bulletin: Viral Hepatitis [Internet]. Brasília: Ministry of Health; 2017 [quoted 2017 Nov 25]. 68 p. Available in: https://central3.to.gov.br/arquivo/387533/

Brazilian Institute of Geography and Statistics (BR). Demographic Census 2010 [Internet]. Brasília: Brazilian Institute of Geography and Statistics; 2011 [quoted 2017 Nov 25]. 270 p. Available in: https://biblioteca.ibge.gov.br/visualizacao/periodicos/93/cd_2010_caracteristicas_populacao_domicilios.pdf

Oliveira TJB. Epidemiological profile of hepatitis C cases in a referral hospital in infectious diseases in the State of Goiás, Brazil. Goiânia. Course Completion Work [Multiprofessional Residency in Infectology] - Secretary of Health of the State of Goiás; 2017. 12 p.

Omland LH, Krarup H, Jepsen P, Georgsen J, Harritshoj LH, Riisom K et al. Mortality in patients with chronic and cleared hepatitis C viral infection: nationwide cohort study. J Hepatol. 2010 jul; 53(1): 36-42.

Vieira AM, Freire R, Mangualde C, Pinho V, Fernandes AL, Alves F et al. Hepatitis C: casuistry of the consultation of hepatology of a district hospital. J Port Gastrenterol. 2007 may; 14 (1): 134-140.

Al-Khurri LE, Al-Khafaji KR, Al-Salihi SA, Alwaysi SA, Al-kayshi RJ. Serum HCV-RNA levels in patients with chronic hepatitis C: correlation with histological features. Arab J Gastroenterol. 2009 mar; 10(1): 10-13.

Shahid M, Idrees M, Nasir B, Raja AJ, Raza SM, Amin I et al. Correlation of biochemical markers and HCV RNA titers with fibrosis stages and grades in chronic HCV-3a patients. Eur J Gastroenterol Hepatol. 2014 jul; 26(7): 788-794.

Silva ACM, Barone AA. Risk factors for HIV infection in patients with hepatitis C virus Rev Saude Publica. 2006 Feb; 40 (3): 482-488.

Strauss E. Hepatitis C. Journal of the Brazilian Society of Tropical Medicine. 2001 jan-fev; 34 (1): 69-82.

Hézode C, Fourati S, Chevaliez S, Scoazec G, Soulier A, Varaut A et al. Sofosbuvir-daclatasvir-simeprevir plus ribavirin in direct-acting antiviral-experienced patients with hepatitis C. Clin Infect Dis. 2017 jun; 64(11): 1615-1618.

Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015 Apr; 61(4):1127-1135.

Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. LO8: Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J Hepatol. Elsevier; 2015 Jun 15;62(Supplement 2): S261–S262.

Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015 nov; 149(6): 1462-1470.

Ministry of Health (BR). Secretariat of Science, Technology and Strategic Inputs. National Commission of Incorporation of Technologies in SUS. Recommendation Report: Extended treatment time HCV - Genotype 3 with Cirrhosis, for 24 weeks. Brasília: Ministry of Health; 2017 [quoted 2017 Nov 25]. 36 p.

Callefi LA. Effectiveness and safety of triple therapy with boceprevir or telaprevir in the treatment of chronic hepatitis C genotype 1 in patients attended at referral centers in Brazil. Sao Paulo. Thesis [PhD in Sciences] - University of São Paulo; 2017. 118 p.




DOI: https://doi.org/10.34117/bjdv7n4-045

Refbacks

  • There are currently no refbacks.